SilicoGenesis

The AI engine Fit Assessment

Beta

SilicoGenesis leverages advanced machine learning technologies to discover new patterns and expand therapeutic options, optimizing the drug discovery process effectively.

Blurb

SilicoGenesis is a biotechnology research firm that specializes in developing antibodies.

HQ Location

Johannesburg (South Africa)

Founded

2021

Employees

1 - 10

Total funding raised

Not available

Funding Status

Not available
Subspaces
  • Drug Discovery Optimization

SilicoGenesis is revolutionizing the field of antibody and biologic design, discovery, and optimization, positioning itself as a leader in the industry.



Our cutting-edge expertise and advanced technologies empower pharmaceutical and biotech companies to expedite and scale up the discovery and optimization of antibody lead molecules. Through our state-of-the-art AI/ML algorithms, in-silico pipelines, and collaborative expert team, we rapidly develop innovative therapeutic lead molecules.



Our comprehensive suite of solutions in the drug discovery pipeline encompasses:



* Precise 3D modeling of protein structures.

* Accurate prediction of paratope and epitope residues.

* Thorough characterization and modeling of protein-protein interactions.

* Enhancement of binding affinity and mutagenesis studies.

* Cross-species reactivity analysis.

* Expert humanization of antibody candidates.

* Rigorous assessment of developability liabilities.



SilicoGenesis has established a strong track record of successful collaborations with numerous pharmaceutical companies, biotech firms, and academic institutions across diverse projects. We are committed to supporting your specific needs and objectives.



To learn more about our transformative capabilities, please visit our website at www.silicogenesis.com.